Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prostate-specific Antigen Velocity (PSAV) and PSAV per Initial Volume (PSAVD) for Early Detection of Prostate Cancer in Chinese Men

  • Zheng, Xiang-Yi (Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine) ;
  • Zhang, Peng (Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine) ;
  • Xie, Li-Ping (Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine) ;
  • You, Qi-Han (Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine) ;
  • Cai, Bo-Sen (Department of Ultrasonography, The First Affiliated Hospital, Zhejiang University School of Medicine) ;
  • Qin, Jie (Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: To investigate the utility of prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer (PCa) in Chinese men. Methods: Between January 2009 and June 2012, a total of 193 men (aged 49-84 years, median 67 years) with at least 2 transrectal ultrasonography (TRUS) procedures and concurrent serum PSA measurements underwent prostate biopsy because of suspicion of PCa. The total group were classified into PCa and non-PCa groups, and the variables of the two groups were compared. Univariate and multivariate analyses were used to investigate which variables were predictove. The diagnostic values of PSAV, PSAVD and prostate-specific antigen density (PSAD) were compared using receiver operating characteristic (ROC) analysis. Results: Prostate cancer was diagnosed in 44 (22.8%) of the 193 men. There were significant differences between the groups in last and initial prostate volumes determined by TRUS, initial age, last serum PSA levels, PSAV, PSAD and PSAVD. After adjusting for confounding factors, the odds ratios of PCa across the quartile of PSAVD were 1, 4.06, 10.6, and 18.9 (P for trend <0.001).The area under the ROC curves (AUCs) of PSAD (0.779) and PSAVD (0.776) were similar and both significantly greater than that of PSA (AUC 0.667). PSAVD was a significantly better indicator of PCa than PSAV (AUC 0.736). There was no statistical significant difference between the AUC of PSAV and that of last serum PSA level. The sensitivity and specificity of PSAVD at a cutoff of 0.023ng in participants with last serum PSA levels of 4.0ng/mL-10.0ng was 73.7% and 70.7%, respectively. Conclusions: The results of this study demonstrated PSAVD may be a useful tool in PCa detection, especially in those undergoing previous TRUS examination.

Keywords

References

  1. Allan RW, Sanderson H, Epstein JI (2003). Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol, 170, 370-2. https://doi.org/10.1097/01.ju.0000074747.72993.cb
  2. Bretton PR, Evans WP, Borden JD, Castellanos RD (1994). The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. Cancer, 74, 2991-5. https://doi.org/10.1002/1097-0142(19941201)74:11<2991::AID-CNCR2820741116>3.0.CO;2-R
  3. Carter HB, Ferrucci L, Kettermann A, et al (2006). Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst, 98, 1521-7. https://doi.org/10.1093/jnci/djj410
  4. Carter HB, Pearson JD, Metter EJ, et al (1992). Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA, 267, 2215-20. https://doi.org/10.1001/jama.1992.03480160073037
  5. Catalona WJ, Southwick PC, Slawin KM, et al (2000). Comparison of percent free psa, psa density, and agespecific psa cutoffs for prostate cancer detection and staging. Urology, 56, 255-60. https://doi.org/10.1016/S0090-4295(00)00637-3
  6. Choi SY, Chang IH, Kim YS, et al (2011). Prostate specific antigen velocity per prostate volume: a novel tool for prostate biopsy prediction. Urology, 78, 874-9. https://doi.org/10.1016/j.urology.2011.03.065
  7. Chang YL, Lin AT, Chen KK, et al (2006). Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia. J Urol, 176, 196-9. https://doi.org/10.1016/S0022-5347(06)00568-4
  8. De Visschere P, Oosterlinck W, De Meerleer G, Villeirs G (2010). Clinical and imaging tools in the early diagnosis of prostate cancer, a review. JBR-BTR, 93, 62-70.
  9. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM (2007). Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst, 99, 1510-5. https://doi.org/10.1093/jnci/djm171
  10. Kawachi MH, Bahnson RR, Barry M, et al (2010). Prostate cancer early detection. J Natl Cancer Inst, 8, 240-62.
  11. Li M, Zhang S, Ma J, Chen W, Na Y (2009). A comparative study on incidence trends of prostate cancer in part of cities and counties in China. Chin J Urol, 30, 568-70.
  12. McLaren DB, McKenzie M, Duncan G, Pickles T (1998). Watchful waiting or watchful progression? Cancer, 82, 342-8. https://doi.org/10.1002/(SICI)1097-0142(19980115)82:2<349::AID-CNCR15>3.0.CO;2-Z
  13. Rhodes T, Girman CJ, Jacobsen SJ, et al (1999). Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol, 161, 1174-9. https://doi.org/10.1016/S0022-5347(01)61621-5
  14. Schmid HP, Riesen W, Prikler L (2004). Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol, 50, 71-8. https://doi.org/10.1016/j.critrevonc.2003.11.001
  15. Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH (2006). Does psa velocity predict prostate cancer in prescreened populations? Eur Urol, 49, 460-5; discussion 5. https://doi.org/10.1016/j.eururo.2005.12.026
  16. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  17. Smith DS, Catalona WJ (1994). Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol, 152, 1163-7. https://doi.org/10.1016/S0022-5347(17)32528-4
  18. Terris MK, Stamey TA (1991). Determination of prostate volume by transrectal ultrasound. J Urol, 145, 984-7. https://doi.org/10.1016/S0022-5347(17)38508-7
  19. Thompson IM, Ankerst DP, Chi C, et al (2006). Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst, 98, 529-34. https://doi.org/10.1093/jnci/djj131
  20. Ulmert D, Serio AM, O'Brien MF, et al (2008). Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol, 26, 835-41. https://doi.org/10.1200/JCO.2007.13.1490
  21. Vickers AJ, Wolters T, Savage CJ, et al (2009). Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol, 56, 753-60. https://doi.org/10.1016/j.eururo.2009.07.047
  22. Wolters T, Roobol MJ, Bangma CH, Schroder FH (2009). Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? european randomized study of screening for prostate cancer (rotterdam). Eur Urol, 55, 385-93. https://doi.org/10.1016/j.eururo.2008.02.046
  23. Xie LP, Bai Y, Zhang XZ, et al (2007). Obesity and benign prostatic enlargement: a large observational study in China. Urology, 69, 680-4. https://doi.org/10.1016/j.urology.2006.12.030
  24. Zheng XY, Xie LP, Wang YY, et al (2008). The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol, 134, 1207-10. https://doi.org/10.1007/s00432-008-0400-8

Cited by

  1. Current Status of Biomarkers for Prostate Cancer vol.14, pp.6, 2013, https://doi.org/10.3390/ijms140611034
  2. A computational bioinformatics analysis of gene expression identifies candidate agents for prostate cancer vol.46, pp.6, 2013, https://doi.org/10.1111/and.12127
  3. Cumulative Probability of Prostate Cancer Detection Using the International Prostate Symptom Score in a Prostate-specific Antigen-based Population Screening Program in Japan vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7079
  4. Utility of Digital Rectal Examination, Serum Prostate Specific Antigen, and Transrectal Ultrasound in the Detection of Prostate Cancer: A Developing Country Perspective vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3087
  5. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5967